Sanofi S.A.
Company History
Sanofi History: Founding, Growth & Key Milestones
Founded 2004 in Paris, France
When was Sanofi founded?
Sanofi was founded in 2004 in Paris, France by Jean-François Dehecq and René Sautier, making it 22 years old.
- Founded
- 2004
- Founding place
- Paris, France
- Founders
- Jean-François Dehecq and René Sautier
- Headquarters today
- Paris, France
- Milestones documented
- 11 (1973–2026)
- Current CEO
- Belén Garijo
- Acquisitions
- 4
| Year | Event |
|---|---|
| 1973 | Sanofi created inside Elf Aquitaine |
| 1999 | Sanofi-Synthélabo formed |
| 2004 | Aventis takeover |
| 2008 | Chris Viehbacher Becomes CEO |
| 2011 | Genzyme acquired |
| 2017 | Dupixent approved |
| 2019 | 'Play to Win' strategy |
| 2023 | Acquired Provention Bio |
| 2025 | Opella control sold; Blueprint acquired |
| 2026 | Belén Garijo becomes CEO |
| 2026 | Olivier Charmeil Named Interim CEO |
- Where was Sanofi founded?
- Sanofi was founded in Paris, France in 2004.
- Who founded Sanofi?
- Sanofi was founded by Jean-François Dehecq and René Sautier.
- When did Sanofi start?
- Sanofi was founded in 2004.
- How old is Sanofi?
- Sanofi is 22 years old as of 2026.
Founding Story
Sanofi began in 1973 as the healthcare subsidiary of the French state-controlled oil group Elf Aquitaine, with Jean-François Dehecq leading it. It grew through acquisitions, merged with L'Oréal's drug unit Synthélabo in 1999, and in 2004 won a hostile takeover of the larger Franco-German Aventis, itself formed from Rhône-Poulenc and Hoechst. The combined Sanofi-Aventis shortened its name to Sanofi in 2011.
Founders
Jean-François Dehecq
Jean-François Dehecq led Sanofi from its creation as Elf Aquitaine's health subsidiary in 1973. He drove the 1999 merger with Synthélabo and the 2004 takeover of Aventis, served as CEO of Sanofi-Aventis until the end of 2006 and remained chairman until 2010. (Exact birth year remains publicly undisclosed).
René Sautier
René Sautier is credited alongside Jean-François Dehecq with setting up Sanofi as Elf Aquitaine's pharmaceutical arm in 1973. Public records on his later role are limited. (Exact birth year remains publicly undisclosed).
Key Milestones
Sanofi created inside Elf Aquitaine
The French oil group sets up Sanofi as its healthcare subsidiary.
Source: en.wikipedia.orgSanofi-Synthélabo formed
Sanofi merges with L'Oréal's pharmaceutical unit Synthélabo.
Source: en.wikipedia.orgAventis takeover
Sanofi-Synthélabo wins a hostile bid for the larger Aventis, creating Sanofi-Aventis.
Source: en.wikipedia.orgChris Viehbacher Becomes CEO
Chris Viehbacher became chief executive of Sanofi-Aventis in December 2008.
Source: en.wikipedia.orgGenzyme acquired
Sanofi buys Genzyme for about $20.1 billion, adding rare disease therapies.
Source: en.wikipedia.orgDupixent approved
The FDA approves Dupixent for atopic dermatitis, starting Sanofi's largest growth franchise.
Source: en.wikipedia.org'Play to Win' strategy
New CEO Paul Hudson refocuses Sanofi on immunology, vaccines and specialty care.
Source: en.wikipedia.orgOpella control sold; Blueprint acquired
Sanofi sells a 50% controlling stake in Opella to CD&R in April and completes the Blueprint Medicines acquisition in July.
Source: sanofi.comBelén Garijo becomes CEO
The board ends Paul Hudson's tenure in February; Garijo takes over after the April 29 AGM.
Source: sanofi.comOlivier Charmeil Named Interim CEO
Olivier Charmeil served as interim chief executive of Sanofi in 2026 between Paul Hudson and Belen Garijo.
Source: sanofi.comMajor Acquisitions
Aventis
2004Sanofi-Synthélabo launched a hostile bid for the larger Franco-German Aventis, with French government support for a domestic combination.
Genzyme
2011Added a rare disease and biologics business based in Cambridge, Massachusetts.
Provention Bio
2023Acquired Tzield, which can delay stage 3 type 1 diabetes.
Blueprint Medicines
2025Added Ayvakit for systemic mastocytosis and a pipeline in KIT-driven diseases.
Keep researching Sanofi
Sanofi Company History FAQ
When and where was Sanofi originally founded?
Sanofi traces its corporate lineage across three centuries to 1718 when Laboratoires Dausse was established in Paris, France. The modern corporate entity was founded in 1973 by French state-owned oil enterprise Elf Aquitaine, merging with Synthélabo in 1999 and executing a hostile takeover of Aventis in 2004.
What was the dramatic 2004 hostile merger that created Sanofi-Aventis?
In early 2004, Sanofi-Synthélabo launched a dramatic €55 billion hostile takeover bid for Franco-German rival Aventis (itself formed from Hoechst and Rhône-Poulenc). Encouraged by the French government to block a rival bid from Swiss giant Novartis, the companies merged on August 20, 2004, creating the world's third-largest pharmaceutical company.
What was the landmark acquisition of Genzyme in 2011?
In February 2011, Sanofi acquired Boston-based biotechnology pioneer Genzyme for $20.1 billion in cash (plus contingent value rights), instantly establishing world-leading dominance in rare genetic disease treatments (Fabry disease, Gaucher disease) and multiple sclerosis.
What is the history of Sanofi's partnership with Regeneron on Dupixent?
In 2007, Sanofi and New York biotech Regeneron entered a landmark antibody collaboration. The partnership yielded Dupixent (dupilumab), an IL-4 and IL-13 inhibitor approved in 2017 that revolutionized the treatment of atopic dermatitis and asthma, becoming one of the bestselling medicines in pharmaceutical history.
What was the commercial impact of Lantus (insulin glargine) on Sanofi?
Introduced in 2000, Lantus was the world's first once-daily long-acting insulin analog, transforming type 1 and type 2 diabetes care and generating over $7 billion in peak annual sales for Sanofi before patent expirations and biosimilar competition eroded sales in the mid-2010s.
Who is Paul Hudson and what transformation did he initiate as CEO in 2019?
Paul Hudson, former CEO of Novartis Pharmaceuticals, was appointed CEO of Sanofi in September 2019. He launched the "Play to Win" strategy: ruthlessly ending cardiovascular and diabetes R&D, doubling down on immunology and rare diseases, scaling Dupixent, and accelerating mRNA vaccines.
What happened during Sanofi's COVID-19 vaccine development in 2020-2021?
Sanofi partnered with GSK on a recombinant protein COVID-19 vaccine, but suffered severe clinical trial delays due to an incorrect formulation dosing error, falling behind mRNA pioneers Pfizer/BioNTech and Moderna in deploying pandemic vaccines, which prompted a major internal R&D overhaul.
What was the breakthrough launch of Beyfortus (nirsevimab) in 2023?
Partnered with AstraZeneca, Sanofi launched Beyfortus in late 2023, the world's first all-infant single-dose monoclonal antibody immunizing newborns against Respiratory Syncytial Virus (RSV) lower respiratory tract disease, which experienced unprecedented global demand and rapid blockbuster adoption.
Why did Sanofi initiate the spinoff of its Consumer Healthcare division (Opella) in 2024?
In October 2024, Sanofi agreed to sell a 50% controlling stake in its Consumer Healthcare business, Opella (maker of Doliprane, Allegra, and Dulcolax), to private equity firm Clayton, Dubilier & Rice (CD&R) for an enterprise valuation of ~€16 billion, transforming Sanofi into a pure-play innovative biopharma company.
Where is Sanofi's global corporate headquarters located?
Sanofi is headquartered on Avenue de la Grande Armée in Paris, France, operating major research and biomanufacturing hubs in Cambridge/Framingham (Massachusetts), Lyon (France), Frankfurt (Germany), and Bridgewater (New Jersey).
When did the company officially drop "Aventis" from its name?
In May 2011, following the Genzyme acquisition and a unified branding push under then-CEO Christopher Viehbacher, shareholders voted to simplify the corporate name from "Sanofi-Aventis" to simply "Sanofi".
What was the acquisition of Translate Bio and Kadmon in 2021?
In 2021, Sanofi acquired mRNA developer Translate Bio for $3.2 billion to establish its in-house Sanofi mRNA Center of Excellence, and acquired Kadmon Holdings for $1.9 billion to add Rezurock for chronic graft-versus-host disease.
Related Strategic History
Compare founding milestones and corporate evolution
Explore Sanofi
Core profile pages, founders and related research hubs for this company.